Key Points
- CMO Harold Bernstein sold 15,000 shares of Maze on March 20 at an average price of $49.10 for $736,500, part of multiple insider sales this year totaling roughly $5.97 million.
- Wall Street sentiment is broadly positive with a consensus rating of 'Buy' and an average price target of $58.56, as several firms (Guggenheim, Wedbush, Mizuho) have raised ratings or targets while one (Weiss) remains negative.
- Maze trades with a market cap of $2.31 billion, a high beta of 4.47, and a 52-week range of $6.71–$53.65, indicating significant volatility and a recent run-up toward its high.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Friday, March 20th. The shares were sold at an average price of $49.10, for a total transaction of $736,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Harold Bernstein also recently made the following trade(s):
- On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00.
- On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00.
- On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20.
- On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00.
- On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
- On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.
Maze Therapeutics Stock Performance
Shares of NASDAQ MAZE opened at $48.03 on Friday. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -2.30 and a beta of 4.47. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $53.65. The firm's 50-day simple moving average is $45.84 and its 200 day simple moving average is $36.82.
Institutional Investors Weigh In On Maze Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc bought a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $227,000. Frazier Life Sciences Management L.P. lifted its stake in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Washington University bought a new position in Maze Therapeutics in the 3rd quarter worth approximately $5,463,000. Virtus Investment Advisers LLC bought a new position in Maze Therapeutics in the 2nd quarter worth approximately $85,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics in the 3rd quarter valued at approximately $14,135,000.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the company. Guggenheim lifted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Mizuho raised Maze Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 11th. Lifesci Capital raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Wedbush increased their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday, March 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $58.56.
View Our Latest Analysis on Maze Therapeutics
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
